Ionis Pharmaceuticals
IONS
304 hedge funds and large institutions have $5.6B invested in Ionis Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 97 increasing their positions, 111 reducing their positions, and 42 closing their positions.
19% more capital invested
Capital invested by funds: $4.69B → $5.6B (+$908M)
3.69% more ownership
Funds ownership: 91.74% → 95.43% (+3.7%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
9% less call options, than puts
Call options by funds: $21.6M | Put options by funds: $23.6M
3% less funds holding
Funds holding: 314 → 304 (-10)
13% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 111
24% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$76.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$40M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$35.2M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$32.3M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$22.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$14.5M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$12.1M |
| 3 |
Renaissance Technologies
New York
|
-$10.2M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$10M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$9.48M |
IONS Hedge Fund Activity: Q2 2023 in Review
304 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2023, worth a combined $5.6B — up 19% from $4.69B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of IONS and 32 opened new positions — a net loss of 10 holders — while 111 trimmed existing stakes and 97 added.
The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $76.2M. The largest seller was Allspring Global Investments, cutting an estimated $14.5M.
- 304 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2023, down from 314 in Q1 2023.
- Funds reported $5.6B of Ionis Pharmaceuticals stock for Q2 2023, up 19% quarter-over-quarter.
- 32 funds opened new Ionis Pharmaceuticals positions in Q2 2023 and 42 closed out, a net change of -10 holders.
- The largest Ionis Pharmaceuticals buyer in Q2 2023 was Pictet Asset Management (Switzerland), an estimated $76.2M added.
- The largest Ionis Pharmaceuticals seller in Q2 2023 was Allspring Global Investments, an estimated $14.5M sold.
Based on aggregated 13F filings for Q2 2023.